Alcami Overview

  • Founded

  • 1979

Founded
  • Status

  • Private

  • Employees

  • 993

Employees
  • Latest Deal Type

  • Buyout/​LBO

  • Financing Rounds

  • 10

  • Investments

  • 4

Alcami General Information

Description

Operator of contract development and manufacturing organization (CDMO) intended for small and mid-sized pharmaceutical and biotechnology companies. The company offers formulation and analytical development, testing, microbial identification, stability storage and other laboratory-related services, enabling clients to avail of a less-fragmented, cost-effective and faster pathway for product commercialization.

Contact Information

Website
www.alcaminow.com
Formerly Known As
Cambridge Major Laboratories
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
BPO/Outsource Services
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
  • 2320 Scientific Park Drive
  • Wilmington, NC 28405
  • United States
+1 (800) 000-0000

Alcami Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alcami Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alcami‘s full profile, request access.

Request a free trial

Alcami Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of contract development and manufacturing organization (CDMO) intended for small and mid-sized pharmaceutical a
BPO/Outsource Services
Wilmington, NC
993 As of 2022
00.00
000000000000

000000

o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000000000000 000000
Toronto, Canada
000 As of 0000
00.00 0000-00-00
000000&0

000000

ugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000000000000 000000
Clearwater, FL
000 As of 0000
0000
000000 - 000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alcami Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dalton Pharma Services Corporate Backed or Acquired Toronto, Canada 000 000000&0
000000 Private Equity-Backed Clearwater, FL 000 0000 000000 - 000
000000 000000 Private Equity-Backed Durham, NC 000 00.00 000000000 00 00.00
0000000000 Private Equity-Backed Cuxhaven, Germany 00 000000000000
000 000000 0000000 Private Equity-Backed Philadelphia, PA 0000 00000 000000000 00000
You’re viewing 5 of 26 competitors. Get the full list »

Alcami Patents

  • 45

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Alcami Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11642324-B1 Topical tranexamic acid compositions and methods of use thereof Active 01-Mar-2022 0000000000 000
AU-2019350525-A1 Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound Pending 26-Sep-2018 0000000000
CA-3112993-A1 Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound Pending 26-Sep-2018 0000000000
EP-3856721-B1 Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound Active 26-Sep-2018 0000000000
EP-3856721-A1 Synthetic method for the preparation of a 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol compound Active 26-Sep-2018 C07D231/38
To view Alcami’s complete patent history, request access »

Alcami Executive Team (24)

Name Title Board Seat Contact Info
Patrick D. Walsh Chief Executive Officer & Chairman of the Board
Eric Evans Chief Financial Officer
Ken Domagalski Chief Operating Officer
Timothy Compton Chief Business Officer
Jamie Iudica Chief Manufacturing Officer
You’re viewing 5 of 24 executive team members. Get the full list »

Alcami Board Members (12)

Name Representing Role Since
0000 000000 GHO Capital Board Member 000 0000
00000 00000 Self Board Member 000 0000
00000000 000000000 Alcami Board Member 000 0000
0000000 00000000 GHO Capital Board Member 000 0000
0000000 00000 Vistria Group Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Alcami Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alcami Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alcami‘s full profile, request access.

Request a free trial

Alcami Investments (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 15-Dec-2021 0000000000 Laboratory Services (Healthcare) 0000000 0
00000000 0000 17-Jan-2020 0000000000 Other Pharmaceuticals and Biotechnology 000000 00
000000000 000 02-Oct-2013 0000000000 Other Pharmaceuticals and Biotechnology
Cambridge Major Laboratories Europe 16-Nov-2007 Buyout/LBO Pharmaceuticals 0000000 0
To view Alcami’s complete investments history, request access »

Alcami Subsidiaries (2)

Company Name Industry Location Founded
Masy Bioservices Laboratory Services (Healthcare) Pepperell, MA 1984
00000000 00000000 Other Pharmaceuticals and Biotechnology Morrisville, NC
To view Alcami’s complete subsidiaries history, request access »

Alcami Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 00000 00 16-Nov-2007 0000000000 Completed
  • 2 buyers
To view Alcami’s complete exits history, request access »